Log in with your email address username.


[Correspondence] Ixekizumab for psoriasis

Christopher Griffiths and colleagues (Aug 8, p 541)1 reported that ixekizumab, a high-affinity antibody targeting interleukin 17A, given to patients with moderate-to-severe psoriasis for 12 weeks had greater efficacy than etanercept and placebo. However, the dermatology life-quality index used in the studies might have been insufficient to assess adverse effects because it only assesses dermatological symptom-associated mental status.